Five takeaways:
1. Knee sales were down 3.5 percent year over year in the U.S., netting $386.3 million. Globally, the revenue decrease was 0.1 percent, and total knee sales were $647.9 million.
2. Hip sales were $244.2 million in the U.S., down 9.1 percent. Global hip sales were down 6.3 percent from the same time last year at $453.8 million.
3. Zimmer Biomet’s spine and dental business, ZimVie, saw a 5.8 percent decrease in revenue year over year. Revenue was $238.6 million.
4. The company’s sports medicine, extremities, trauma, craniomaxillofacial and thoracic business saw a 4.9 percent year-over-year increase in sales at $437.6 million.
5. Highlights for Zimmer Biomet from the third quarter include FDA approval of the Rosa hip system for robotic surgery and FDA de novo classification for the tibial extension for Persona IQ, a smart knee implant.
